Understand the source comparison
Comparison: Tesofensine Thermogenesis vs Traditional Stimulants
The following table compares tesofensine's thermogenic profile against commonly used metabolic stimulants across mechanism, metabolic increase, cardiovascular impact, and tolerance development: Tesofensine (0.25–0.5mg) Triple monoamine reuptake inhibition (SER
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares tesofensine's thermogenic profile against commonly used metabolic stimulants across mechanism, metabolic increase, cardiovascular impact, and tolerance development:
- Tesofensine (0.25–0.5mg)
- Triple monoamine reuptake inhibition (SERT/NET/DAT)
- 6–10% sustained
- Mild. 5–10 bpm heart rate increase, minimal blood pressure elevation
- Minimal over 12 weeks
- Most sustainable thermogenic option. No receptor downregulation, steady metabolic lift without sympathetic overdrive
- Ephedrine (25mg 3x/day)
- Direct beta-adrenergic agonist + norepinephrine release
- 8–12% acute
- Moderate. 15–25 bpm increase, systolic BP +10–15mmHg
- Tolerance within 7–14 days
- Effective short-term but rapid beta-receptor desensitisation limits prolonged use. Cardiovascular risk elevated in sensitive populations
- Clenbuterol (40–120mcg)
- Selective beta-2 adrenergic agonist
- 10–15% acute
- High. Tachycardia, tremors, electrolyte disturbances
- Tolerance within 48–72 hours
- Potent but unsustainable. Beta-2 receptor downregulation requires cycling (2 weeks on/off), cardiac hypertrophy risk at chronic use
- Caffeine (400mg)
- Adenosine receptor antagonist + phosphodiesterase inhibition
- 3–5% transient
- Low. Minimal heart rate change, slight BP elevation
- Partial tolerance within 5–7 days
- Weakest thermogenic effect but best safety profile. Synergises with other compounds but limited standalone metabolic impact
- Yohimbine (10–20mg)
- Alpha-2 adrenergic antagonist
- 2–4% transient
- Moderate. Anxiety, tachycardia in sensitive individuals
- Minimal tolerance
- Enhances catecholamine effects in stubborn fat depots but minimal whole-body thermogenesis. Best as adjunct, not primary thermogenic
- Tesofensine's advantage is duration without tolerance. Traditional beta-agonists create dramatic initial metabolic surges but receptor downregulation occurs within days. The body adapts by reducing receptor density. Tesofensine doesn't directly activate receptors, so downregulation doesn't occur. Norepinephrine availability remains elevated as long as the reuptake transporter remains blocked.